Sheila Zipfel is a proven medicinal chemistry leader, inventor, and MBA with more than 25 years of experience spanning roles at Gilead Sciences and Celera Genomics. Her career highlights include the design of voxilaprevir, a key component of the hepatitis C cure Vosevi®, and the advancement of multiple drug discovery programs from early screening through Phase 1 development.

Bridging deep scientific expertise with business strategy, Sheila has also led product management efforts in the tech startup space at Nanome. Today, through Zipfel Drug Discovery, she provides strategic advisory services and fractional leadership to innovators in medicinal chemistry, scientific staffing, and AI-driven drug discovery.